MAA Laboratories Inc.
Biotech · Private
Nanoformulation drug delivery technology (NanoContTM) that creates stable pharmaceutical nanocrystals (~100 nm) with improved solubility and bioavailability for poorly soluble drugs like dasatinib
maalaboratories.com →- Grants
- $925K
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 4
- 2 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: The novel NanoCont drug delivery technology for creating nanoformulated medicines with improved safety, better quality, and more predictable clinical responses. | $225,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Novel Nanodrug Delivery System to Optimize Dose of Oncology Drugs | $300,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Novel Nanodrug Delivery System to Optimize Dose of Oncology Drugs | $350,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Nanodrug Delivery System to Optimize Dose of Oncology Drugs | $50,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3014 | CIRCUMVENT PHARMACEUTICALS, INC. | — | — |
| 3015 | Recodagen LLC | — | — |
| 3016 | DeepMind | — | — |
| 3017 | MAA Laboratories Inc. | — | — |
| 3018 | GLYCOMANTRA INC | — | — |
| 3019 | AQUILUS PHARMACEUTICALS INC | — | — |
| 3020 | Dualogics LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods Of Improving The Solubility And Bioavailability Of Therapeutic Agentsgranted
- Methods Of Improving The Solubility And Bioavailability Of Therapeutic Agentsgranted
- Methods Of Improving The Solubility And Bioavailability Of Therapeutic Agentsapplication
- Methods of Improving the Solubility and Bioavailability of Therapeutic Agentsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.